A randomized, double-blind, placebo-controlled phase II study of CERC-301 for the adjunctive treatment of major depressive disorder

Trial Profile

A randomized, double-blind, placebo-controlled phase II study of CERC-301 for the adjunctive treatment of major depressive disorder

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Nov 2016

At a glance

  • Drugs CERC 301 (Primary)
  • Indications Major depressive disorder
  • Focus Therapeutic Use
  • Most Recent Events

    • 08 Nov 2016 Top-line results from this trial are expected in November 2016, according to a Cerecor Inc. media release.
    • 01 Oct 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top